What is the Purpose of this Study?
The purpose of this study is to evaluate an investigational drug called AV-101 in patients with pulmonary arterial hypertension (PAH). Researchers aim to determine the effects of AV-101 on people with PAH over a longer period of time. This study is a long-term extension study of people who completed another study (AV-101-002), a 24-week study of AV-101 in people with PAH. AV-101 is an investigational dry powder of imatinib that is inhaled into the lungs via the mouth. Imatinib is involved in blocking enzymes that may activate proteins that cause the pulmonary arteries to thicken, making it difficult for blood to flow between the lungs and the heart. All participants in this study will receive AV-101 treatment.
Eligibility
- To be eligible, a participant is required to be or have:
- Consented to participate in the LTE and has successfully completed the placebo-controlled 24-week Study AV-101-002.
Where can I participate?
Beverly
More about this Clinical Trial
What is the full name of this clinical trial?
IMPAHCT-FUL : A Long-Term Extension, Multi-Center Safety Study of AV-101 in Subjects With Pulmonary Arterial Hypertension Who Have Completed Study AV-101-002.